Clinical Trial

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Study acronym: AL
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2023-04-25; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2023-12-21
Trial Details
NCT Number NCT05844982
Lead Sponsor Jaeb Center for Health Research
Collaborators: National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc.
Conditions Radiation Retinopathy, Visual Impairment
Enrollment 600 participants
Start Date 2023-11-21
Primary Completion 2029-12-26 (estimated)
Study Completion 2029-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-16